Avelumab and Pepinemab

Phase 2

Vaccinex, Inc. (VCNX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Metastatic Pancreatic Adenocarcinoma

CLVSCO-1.01

Phase 2

View Full Landscape

Drug Information

Target Indication

Metastatic Pancreatic Adenocarcinoma

Clinical Trial

NCT05102721

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/18/2017

Bavencio

Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC). Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Bavencio is indicated as monotherapy for the first?line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum?based chemotherapy.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

VCNX

Vaccinex, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)Phase 3

Human Papillomavirus (HPV) Infection

11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)Phase 3

HPV InfectioN